Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2017

Open Access 01-12-2017 | Review

Genetics of vascular dementia – review from the ICVD working group

Authors: M. Arfan Ikram, Anna Bersano, Raquel Manso-Calderón, Jian-Ping Jia, Helena Schmidt, Lefkos Middleton, Benedetta Nacmias, Saima Siddiqi, Hieab H.H. Adams

Published in: BMC Medicine | Issue 1/2017

Login to get access

Abstract

Background

Vascular dementia is a common disorder resulting in considerable morbidity and mortality. Determining the extent to which genes play a role in disease susceptibility and their pathophysiological mechanisms could improve our understanding of vascular dementia, leading to a potential translation of this knowledge to clinical practice.

Discussion

In this review, we discuss what is currently known about the genetics of vascular dementia. The identification of causal genes remains limited to monogenic forms of the disease, with findings for sporadic vascular dementia being less robust. However, progress in genetic research on associated phenotypes, such as cerebral small vessel disease, Alzheimer’s disease, and stroke, have the potential to inform on the genetics of vascular dementia. We conclude by providing an overview of future developments in the field and how such work could impact patients and clinicians.

Conclusion

The genetic background of vascular dementia is well established for monogenic disorders, but remains relatively obscure for the sporadic form. More work is needed for providing robust findings that might eventually lead to clinical translation.
Literature
1.
Gorelick PB, et al.; on behalf of the American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–713.
2.
Bergem ALM, Engedal K, Kringlen E. The role of heredity in late-onset Alzheimer disease and vascular dementia: a twin study. Arch Gen Psychiatry. 1997;54:264–70.CrossRefPubMed
3.
4.
Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M-G. Cadasil. Lancet Neurol. 2009;8:643–53.CrossRefPubMed
5.
Pastores GM, Lien Y-HH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol. 2002;13:S130–3.PubMed
6.
Clarke JTR. Narrative review: Fabry disease. An Intern Med. 2007;146:425–33.CrossRef
7.
Bersano A, et al. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurol Scand. 2012;126:77–97.CrossRefPubMed
8.
Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry disease in stroke patients—a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:985–92.CrossRefPubMed
9.
Rolfs A, et al. Acute cerebrovascular disease in the young the stroke in young Fabry patients study. Stroke. 2013;44:340–9.CrossRefPubMed
10.
Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease a systematic review. Stroke. 2010;41:e513–8.CrossRefPubMed
11.
Winkler DT, et al. Hereditary systemic angiopathy (HSA) with cerebral calcifications, retinopathy, progressive nephropathy, and hepatopathy. J Neurol. 2008;255:77–88.CrossRefPubMed
12.
Siveke JT, Schmid H. Evidence for systemic manifestations in cerebroretinal vasculopathy. Am J Med Genet Part A. 2003;123A(3):309.CrossRefPubMed
13.
Richards A, et al. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39:1068–70.CrossRefPubMed
14.
Weil S, et al. Cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome. Neurology. 1999;53(3):629–31.CrossRefPubMed
15.
DiFrancesco JC, et al. TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci. 2014;36:323–30.CrossRefPubMed
16.
Fukutake T. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): from discovery to gene identification. J Stroke Cerebrovasc Dis. 2011;20:85–93.CrossRefPubMed
17.
Nozaki H, et al. Characteristic features and progression of abnormalities on MRI for CARASIL. Neurology. 2015;85:459–63.CrossRefPubMed
18.
Nozaki H, Nishizawa M, Onodera O. Features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2014;45:3447–53.CrossRefPubMed
19.
Cordeiro IM, et al. Shifting the CARASIL paradigm report of a non-asian family and literature review. Stroke. 2015;46:1110–2.CrossRef
20.
Bianchi S, et al. Two novel HTRA1 mutations in a European CARASIL patient. Neurology. 2014;82:898–900.CrossRefPubMed
21.
22.
23.
Yin Y-W, et al. Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: a meta-analysis. Neurosci Lett. 2012;514:6–11.CrossRefPubMed
24.
Zeng L, et al. Can Chinese herbal medicine adjunctive therapy improve outcomes of senile vascular dementia? Systematic review with meta-analysis of clinical trials. Phytother Res. 2015;29:1843–57.CrossRefPubMed
25.
Skrobot OA, et al. A validation study of vascular cognitive impairment genetics meta-analysis findings in an independent collaborative cohort. J Alzheimers Dis. 2016;53:981–9.CrossRefPubMed
26.
Alam R, et al. Synergistic epistasis of paraoxonase 1 (rs662 and rs85460) and apolipoprotein E4 genes in pathogenesis of Alzheimer’s disease and vascular dementia. Am J Alzheimers Dis Other Demen. 2014;29(8):769–76.CrossRefPubMed
27.
Dantoine TF, et al. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. An N Y Acad Sci. 2002;977:239–44.CrossRef
28.
Helbecque N, Cottel D, Codron V, Berr C, Amouyel P. Paraoxonase 1 gene polymorphisms and dementia in humans. Neurosci Lett. 2004;358:41–4.CrossRefPubMed
29.
Zuliani G, et al. Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia. Acta Neurol Scandin. 2001;103:304–8.CrossRef
30.
Bednarska-Makaruk ME, et al. Paraoxonase 1 (PON1) gene-108C > T and p. Q192R polymorphisms and arylesterase activity of the enzyme in patients with dementia. Folia Neuropathol. 2013;51:111–9.CrossRefPubMed
31.
McCusker SM, et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet. 2001;357:436–9.CrossRefPubMed
32.
Fung HC, et al. Heat shock protein 70 and tumor necrosis factor alpha in Taiwanese patients with dementia. Dement Geriatr Cogn Disord. 2005;20:1–7.CrossRefPubMed
33.
Kim Y, Lee C. The gene encoding transforming growth factor β1 confers risk of ischemic stroke and vascular dementia. Stroke. 2006;37:2843–5.CrossRefPubMed
34.
Peila R, et al. A TGF-β1 polymorphism association with dementia and neuropathologies: the HAAS. Neurobiol Aging. 2007;28:1367–73.CrossRefPubMed
35.
Sun J-H, et al. Genetics of vascular dementia: systematic review and meta-analysis. J Alzheimers Dis. 2015;46:611–29.CrossRefPubMed
36.
Liu H, et al. The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: a meta-analysis. J Neurol Sci. 2010;294:74–80.CrossRefPubMed
37.
Dwyer R, Skrobot OA, Dwyer J, Munafo M, Kehoe PG. Using Alzgene-like approaches to investigate susceptibility genes for vascular cognitive impairment. J Alzheimers Dis. 2013;34:145–54.PubMed
38.
Kim Y, Kong M, Lee C. Association of intronic sequence variant in the gene encoding spleen tyrosine kinase with susceptibility to vascular dementia. World J Biol Psychiatry. 2013;14:220–6.CrossRefPubMed
39.
Schrijvers EMC, et al. Genome-wide association study of vascular dementia. Stroke. 2012;43:315–9.CrossRefPubMed
40.
41.
Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium; Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2016;15(7):695–707.CrossRef
42.
Bellenguez C, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet. 2012;44:328–33.CrossRefPubMed
43.
44.
45.
Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatr. 2015;77:43–51.CrossRef
46.
Verhaaren BFJ, et al. Multi-ethnic genome-wide association study of cerebral white matter hyperintensities on MRI. Circ Cardiovasc Genet. 2015;8(2):398–409.CrossRefPubMedPubMedCentral
47.
Verhaaren BFJ, et al. Replication study of chr17q25 with cerebral white matter lesion volume. Stroke. 2011;42:3297–99.CrossRefPubMed
48.
Tabara Y, et al. Association of Chr17q25 with cerebral white matter hyperintensities and cognitive impairment: the J‐SHIPP study. Eur J Neurol. 2013;20:860–2.CrossRefPubMed
49.
50.
51.
Debette S, et al. Genome-wide association studies of MRI-defined brain infarcts meta-analysis from the CHARGE consortium. Stroke. 2010;41:210–7.CrossRefPubMed
52.
53.
Bersano A, et al. Next generation sequencing for systematic assessment of genetics of small-vessel disease and lacunar stroke. J Stroke Cerebrovasc Dis. 2015;24:759–65.CrossRefPubMed
54.
Perneczky R, et al. Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. BMC Med. 2016;14:162.CrossRefPubMedPubMedCentral
55.
56.
Charidimou A, et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiatry. 2013;84:624–9.CrossRefPubMedPubMedCentral
57.
de Groot M, et al. Changes in normal-appearing white matter precede development of white matter lesions. Stroke. 2013;44:1037–42.CrossRefPubMed
58.
Hachinski V, et al. National Institute of Neurological Disorders and Stroke–Canadian stroke network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220–41.CrossRefPubMed
59.
Roses AD, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenom J. 2010;10:375–84.CrossRef
60.
Roses AD, et al. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014;14:81–9.CrossRefPubMed
61.
McCarthy AD, Kennedy JL, Middleton LT. Pharmacogenetics in drug development. Philosoph Trans Royal Soc B. 2005;360:1579–88.CrossRef
Metadata
Title
Genetics of vascular dementia – review from the ICVD working group
Authors
M. Arfan Ikram
Anna Bersano
Raquel Manso-Calderón
Jian-Ping Jia
Helena Schmidt
Lefkos Middleton
Benedetta Nacmias
Saima Siddiqi
Hieab H.H. Adams
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2017
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-017-0813-9

Other articles of this Issue 1/2017

BMC Medicine 1/2017 Go to the issue

Review

Emerging concepts in liquid biopsies

Research article

Systematic meta-review of supported self-management for asthma: a healthcare perspective

Review

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects

Research article

Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients

Debate

Innovative regenerative medicines in the EU: a better future in evidence?

Research article

Synergistic effect of IL-12 and IL-18 induces TIM3 regulation of γδ T cell function and decreases the risk of clinical malaria in children living in Papua New Guinea